Axsome Therapeutics (AXSM) Non-Current Debt (2016 - 2026)

Axsome Therapeutics' Non-Current Debt history runs 11 years deep, the most recent figure standing at $117.8 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 35.02% year-over-year to $117.8 million; the TTM figure through Mar 2026 stood at $117.8 million (down 35.02% YoY), while the FY2025 annual figure was $117.7 million, down 34.84% from the prior year.
• Non-Current Debt came in at $117.8 million for Q1 2026 at Axsome Therapeutics, roughly flat from $117.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $181.4 million in Q1 2025 to a low of $49.3 million in Q1 2022.
• A 5-year average of $140.1 million and a median of $147.6 million in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt jumped 199.35% in 2023 and sank 35.02% in 2026, its largest moves.
• Axsome Therapeutics' Non-Current Debt stood at $94.3 million in 2022, then surged by 88.92% to $178.1 million in 2023, then gained by 1.48% to $180.7 million in 2024, then tumbled by 34.84% to $117.7 million in 2025, then climbed by 0.09% to $117.8 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $117.8 million, $117.7 million, and $117.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison